Opendata, web and dolomites

I-DireCT SIGNED

Immune DIREcted and Cancer-selective immunoTherapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 I-DireCT project word cloud

Explore the words cloud of the I-DireCT project. It provides you a very rough idea of what is the project "I-DireCT" about.

assume    sciences    discoveries    checkpoints    immunomodulatory    appointed    immunostimulatory    inter    immunology    multidisciplinary    uniquely    scientists    optimal    bispecific    immunotherapeutic    expertise    antibodies    outstanding    cancer    chemistry    bio    qualified    revolutionized    breakthrough    carry    ranging    release    innovative    eid    operations    stage    immune    industry    ideas    academia    months    pivotal    nanotech    central    material    co    cutting    active    hereby    academic    science    timed    expanding    oncology    formulations    disciplines    immunocytokines    network    positions    young    career    esr    scientific    fosters    disciplinary    optimized    industrial    hereto    additional    secondments    designed    antibody    physical    off    edge    immunotherapy    tumor    direct    doctorate    carefully    issue    immunotherapeutics    bilateral    biomedical    generation    restricted    sectoral    drug    generate    limits    commercial    array    training    core    engineering    translate    18    combines   

Project "I-DireCT" data sheet

The following table provides information about the project.

Coordinator
ACADEMISCH ZIEKENHUIS GRONINGEN 

Organization address
address: HANZEPLEIN 1
city: GRONINGEN
postcode: 9713 GZ
website: www.umcg.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 2˙533˙358 €
 EC max contribution 2˙533˙358 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2018
 Funding Scheme MSCA-ITN-EID
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2022-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ACADEMISCH ZIEKENHUIS GRONINGEN NL (GRONINGEN) coordinator 929˙669.00
2    INOCURE SRO CZ (PRAHA) participant 587˙178.00
3    Surflay Nanotec GmbH DE (BERLIN) participant 505˙576.00
4    UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT DE (WURZBURG) participant 379˙182.00
5    KAHR MEDICAL LTD IL (JERUSALEM) participant 131˙750.00

Map

 Project objective

I-DireCT is a European Industrial Doctorate (EID) training network designed to provide training and carry out breakthrough research on the rapidly expanding and high impact field of cancer immunotherapy in a carefully integrated academic and inter-sectoral programme. Hereby, we aim to develop next-generation immunotherapeutics and deliver a set of early stage researchers uniquely qualified for a career in academia and/or industry.

Current immunomodulatory antibodies that target pivotal immune checkpoints have revolutionized the field of oncology. However, off-tumor activity limits their application. The objective of I-Direct is to address this issue by 1. developing innovative bispecific antibodies and immunocytokines with tumor-restricted immunostimulatory effects and 2. developing optimized delivery systems to ensure optimal timed release of bio-active drug. Hereto, I-DireCT combines state-of-the-art industrial design of nanotech-based drug formulations with innovative academic and industrial immunotherapeutic concepts into the next-generation of cancer immunotherapeutics.

At the core of I-DireCT is its training objective to offer a cutting-edge multidisciplinary training programme that will enable outstanding young scientists to generate breakthrough ideas and assume leading positions in academia and industry. This training programme includes an array of disciplines, ranging from biomedical sciences (e.g. immunology, antibody engineering) and physical sciences (e.g. chemistry, material science) to drug design & development.

Industrial partners are central to the programme and provide pivotal inter-sectoral expertise on how to translate scientific discoveries into commercial reality, with each ESR being appointed at an inter-sectoral partner for 18 months, as well as through additional secondments. Further, I-Direct will enable long-term multi-disciplinary research and fosters bilateral co-operations between academia and industry.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "I-DIRECT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "I-DIRECT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

FLOAWER (2019)

FLOAting Wind Energy netwoRk

Read More  

UBIMOTIF (2019)

Short linear interaction motifs as specificity determinants in the ubiquitin system – discovery, mechanisms and therapeutic opportunities

Read More  

ACO (2019)

AstroChemical Origins

Read More